The
Skinny Jab

After you eat, your small intestine releases a hormone called GLP-1 — glucagon-like peptide-1. It does several things simultaneously: it signals the pancreas to release insulin, it slows the rate at which your stomach empties, and — critically — it travels to the hypothalamus in your brain and tells it you are full. The sensation of satiety you feel after a meal is, in part, GLP-1 at work.

The problem is that natural GLP-1 is degraded by an enzyme called DPP-4 within minutes of being released. Your body produces it, uses it briefly, and destroys it. The pharmaceutical insight behind semaglutide was to engineer a molecule that mimics GLP-1 but resists that degradation — surviving in the bloodstream for days rather than minutes. A weekly injection of semaglutide keeps your brain in a state of mild, sustained satiety. You are not hungry. You eat less. You lose weight.

This is why the weight loss effect was so surprising to the researchers who first observed it. The drugs were being trialled for glycaemic control in type 2 diabetics. The participants were also losing, in some cases, 15% of their body weight. That was not the hypothesis being tested. It was, in clinical trial terms, an extremely inconvenient distraction — until someone realised it was the most commercially valuable pharmaceutical finding in a generation.

Tirzepatide — sold as Mounjaro — goes further still. It is a "twincretin": a single molecule that activates both the GLP-1 receptor and a second receptor called GIP (glucose-dependent insulinotropic polypeptide). GIP has its own appetite-suppressing and metabolic effects. The combination appears to be synergistic. In the SURMOUNT-1 trial, participants on the highest dose of tirzepatide lost an average of 22.5% of their body weight over 72 weeks. That is not a diet. That is approaching the weight loss achieved by bariatric surgery.

There is, however, a catch that the manufacturers have not been eager to advertise. When you stop taking these drugs, you regain the weight. A 2022 study in the journal Diabetes, Obesity and Metabolism found that participants who stopped semaglutide regained two-thirds of their prior weight loss within a year. A 2026 Lancet analysis confirmed the pattern: by 52 weeks after stopping, patients had regained 60% of what they had lost. The biology is straightforward: the drug was suppressing your appetite artificially. Remove the drug, and your appetite returns. Your body was never reprogrammed — it was merely overridden.

This is not a course of treatment. It is a subscription. The business model, as we will see, is built around exactly that.

In March 2023, NICE — the National Institute for Health and Care Excellence — approved semaglutide (Wegovy) for weight management on the NHS. This was, on paper, a significant moment. A drug with genuine clinical efficacy, approved for a condition that costs the NHS £6.5 billion per year to treat. The approval should have meant widespread access. What it actually meant was considerably more complicated.

NICE approves drugs using a cost-effectiveness framework. The central metric is the QALY — the quality-adjusted life year, a measure that combines the length and quality of life gained from a treatment. NICE's threshold is £20,000–£30,000 per QALY gained. A treatment that costs more than this per QALY is, in NICE's framework, not cost-effective enough to recommend for routine NHS use. Wegovy was approved — but only for patients referred to specialist Tier 3 or Tier 4 weight management services, with a BMI of 35 or above and at least one weight-related comorbidity, and for a maximum of two years. These are not the conditions under which most obese people in Britain live. Tier 3 weight management services are specialist, underfunded, and have waiting lists measured in years.

The cost arithmetic is brutal. The NHS list price for Mounjaro is approximately £293 per patient per month — though the NHS negotiates confidential discounts with manufacturers, so the actual cost is lower. Even at a discounted rate, prescribing Mounjaro to all 3.4 million eligible patients would cost the NHS somewhere between £3 billion and £6 billion per year. The NHS's total medicines budget is approximately £20 billion. The maths does not work without either a dramatic price reduction or a dramatic narrowing of eligibility criteria.

The NHS spends approximately £6.5 billion per year treating the complications of obesity — type 2 diabetes, cardiovascular disease, joint disease, certain cancers. The theoretical argument for mass GLP-1 prescribing is compelling: if you reduce obesity rates, you reduce these downstream costs. The drugs pay for themselves, eventually. The NHS's own modelling suggests that widespread GLP-1 use could save billions over a 10–20 year horizon.

The problem is that "eventually" and "10–20 years" are not useful timeframes for a health service operating under annual budget constraints. The upfront cost is real and immediate. The savings are uncertain and distant. A health secretary who approves mass GLP-1 prescribing in 2026 will not be in post to see the cardiovascular savings in 2036. The incentive structure of democratic healthcare systems is not designed to make this calculation easy.

There are two further controversies that receive less public attention but are arguably more urgent.

The first is the supply problem. GLP-1 drugs were originally developed for type 2 diabetes. Millions of diabetic patients depend on them for blood sugar control — not weight loss. When private demand for weight loss surged from 2022 onwards, it created supply shortages that directly affected diabetic patients. In 2023 and 2024, the UK Department of Health issued repeated warnings about GLP-1 shortages. Diabetic patients found their prescriptions unfulfilled because private weight loss patients had consumed the available supply. This is not a theoretical equity concern. It is a documented clinical harm.

The second is the counterfeit problem. The MHRA — the UK medicines regulator — issued warnings in 2023 about fake Ozempic and Saxenda pens being sold online. The WHO issued a global alert in June 2024. By early 2026, experts were warning that counterfeit oral GLP-1 tablets — easier to manufacture and harder to authenticate than injections — could flood the UK market. Patients accessing these drugs through unregulated online channels, without clinical supervision, face risks that range from receiving an ineffective placebo to receiving a dangerous adulterant.

The GLP-1 story is not, at its core, a story about obesity. It is a story about how pharmaceutical innovation interacts with healthcare systems that were not designed to absorb it. The NHS was built on the premise that medical advances would be available to all, regardless of ability to pay. GLP-1s have exposed the limits of that premise in real time.

The drug works. The evidence is not seriously contested. It produces clinically meaningful weight loss, reduces cardiovascular events, and may prove to have effects on neurological and metabolic health that we are only beginning to understand. The question is not whether it should be available — it is who gets to decide who receives it, and on what basis.

The current answer, in Britain, is: wealthy people get it now, and everyone else waits for a postcode lottery that may or may not resolve in their favour. That is not a policy position anyone has explicitly chosen. It is the emergent outcome of a system where NICE approval does not equal NHS access, where ICBs have discretion over implementation, and where the private market has moved faster than the public system can follow.

The pharmaceutical companies are not villains in this story — they invested billions in R&D, took the risk that the drugs might not work, and priced the resulting products to recover that investment. The NHS is not a villain either — it is a system operating under genuine resource constraints, making difficult prioritisation decisions with imperfect information. The controversy is structural, not moral. The system produces this outcome because it is designed in a way that makes this outcome inevitable.

What changes this is either a dramatic price reduction — which generics will eventually provide — or a political decision to fund GLP-1s at scale, accepting the short-term budget impact in exchange for the long-term health gains. Neither of those things is imminent. In the meantime, 1.5 million Britons are paying £200 a month for a drug their taxes nominally fund, and 3.4 million more are waiting for a system that approved the drug but cannot afford to prescribe it.

The deeper irony is this: the drug that was accidentally discovered while treating diabetes may turn out to be one of the most important pharmaceutical breakthroughs of the century. The SELECT trial data, the Alzheimer's signals, the addiction research — if even a fraction of these secondary effects prove out in Phase 3 trials, the cost-effectiveness calculation changes entirely. A drug that prevents heart attacks, delays dementia, and reduces alcohol dependency is not a weight loss drug. It is something much more significant, and the debate about whether the NHS can afford to prescribe it will look, in retrospect, like arguing about the cost of penicillin.

We are not there yet. But the direction of travel is clear. The question is whether the system can hold together long enough to find out.